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From April to December 1987, after having
carried out rodent neurografting studies, we
performed adrenal medulla autotransplantation
on three patients with severe Parkinson’s dis-
ease. From January 1988 to April 1990, thirty
parkinsonian patients underwent foetal ventral
mesencephalic tissue transplantation in the
caudate nucleus, using an open microsurgical
procedure.
The stereotactic neurotransplantation tech-
nique was first applied in Cuba in March 1992.
Five patients with idiopathic Parkinson’s disease
(Hoehn & Yahr Stage 4) were selected accord-
ing to CAPIT criteria. Their mean age at time of
surgery was 51 years, the evolution time of the
disease ranged from 7 to 13 years; and they had
been receiving L-Dopa for a mean period of 9
years. All of them had motor complications
associated with chronic L-Dopa therapy, such as
dyskinesias, freezing, and complex fluctuations
in motor condition. The presurgical mean "off’
time was 57.6% of the waking day, but in "on"
conditions the patients spent 11.2% of the day
with disabling dyskinesias.
Using the Leksell Stereotactic System, we
performed computer-assisted CT-guided stereo-
tactic transplantation of foetal ventral mesen-
cephalic cell suspensions, into the right caudate
and putamen. The post-conception ages of
foetuses were 8-13 weeks; the mean time be-
tween abortion and implantation was 2 hours 42
minutes; and the graft cell viability ranged from
52 to 80%.
The clinical assessment of the patients carried
out during twelve months before surgery and
three months after transplantation revealed a
progressive reduction in both the daily time
spent in "off’ conditions from 57.6% before
surgery to 12.5% three months after transplanta-
tion, and the number of daily "off’ periods per
day from 4.4 to 1.5.
In the 3rd post-operative month, the patients
showed, as a general pattern, a significant
improvement in their neurological performance
(from 108.8 to 59.5 in I[DRS), a less severe dis-
ability during "off’ periods (Fig. 1), and increase
of "on" time predominantly without dyskinesias
(from 31 to 89%), according to international
rating scales for Parkinson’s disease.
Timed neurological tests were performed in
the post-surgical periods before and after the
first daily L-Dopa dose. Beginning in the 7th
week after grafting there was a significant bi-
lateral improvement of movement speed in both
"off’ and "on" periods, mainly contralateral to
the transplantation site, and a progressive
reduction of the pre-surgical differences
between "off’ and "on" performance time.
In the post-operative stage, we adopted the
pharmacotherapeutic strategy of administering
L-Dopa in slowly increasing doses, to obtain the
best neurological conditions. The patients’
sensitivity to L-Dopa increased after transplan-
tation, allowing us a wider time interval between
doses, and a gradual reduction of the mean dose
from 1000 mg per day before surgery to 409.5
mg daily, three months after implantation.
Dopaminergic drug responses were assessed
before and after surgery. The results of the
pharmacological tests proved post-operative
changes in the pattern of the single dose L-Dopa
response: the motor performance improved sig-
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Clinical evolution from 12 months before to 3 months after transplantation.
Progressive clinical improvement statistically significant from to 3 months after grafting (P_<O.05)
(Wilcoxon matched pairs test).
nificantly, the "on" latency shortened from 76
minutes pre-surgery to 25 minutes three months
after grafting, and the beneficial time-effect of
L-Dopa increased from 84 minutes before to 265
minutes in the 3rd post-operative month.
The post-surgical improvement in our
patients can be summarized as follows-
Motor complications associated with L-Dopa
therapy: redneed.
Response to L-Dopa treatment: improved.
Daily requirements of L-Dopa: redneed.
Parkinsonian symptoms: redneed.
Neurological performance: improved.
Quality of life: improved.
Finally, based on the research conducted over
more than four years in the field of neural
transplantation and as a result of our most
recent experiences, we conclude that transplan-
tation of dopaminergic cells may improve the
neurological condition of parkinsonian patients
suffering from motor complications associated
with L-Dopa therapy.